Pharmaceuticals, 2019 · DOI: 10.3390/ph12020065 · Published: April 29, 2019
Spinal cord injury (SCI) is a devastating condition with limited effective treatments. Neural stem cells (NSCs) offer a potential therapeutic approach by regenerating damaged tissue. NSCs can differentiate into various neural cell types, provide neurotrophic support, and restore synaptic connectivity, making them particularly relevant for SCI treatment. Clinical trials have been launched to assess the safety and efficacy of NSC-based therapies in SCI patients, marking a significant step towards translating experimental findings into clinical applications.
NSC-based therapies are moving towards clinical application with ongoing trials assessing safety and efficacy in SCI patients.
The use of iPSC-derived NSCs allows for autologous transplantation, minimizing the risk of immune rejection and enabling personalized treatment strategies.
Combining NSC transplantation with other therapies, such as ChABC treatment or biomaterials, may enhance regenerative outcomes in SCI.